Incyte (INCY) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45337C1027

(NASDAQ:INCY Stock) Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Incyte (INCY) - Stock Price & Dividends

INCY Stock Overview

Market Cap in USD 12,962m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1993-11-04

INCY Stock Ratings

Fundamental 6.89
Dividend -
Growth 5y -3.75
Rel. Performance vs Sector -3.72
Analysts 4.00
Fair Price Total Ret. 52.66
Fair Price DCF 67.86

INCY Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

INCY Growth Ratios

Growth 12m -23.16%
Growth Correlation 12m -53%
Growth Correlation 3m 8%
CAGR 5y -7.02%
CAGR / Mean Drawdown -0.27
Sharpe Ratio 12m -1.13
Alpha vs SP500 12m -41.00
Beta vs SP500 5y weekly 0.59
CAPM 6.85%
Average Daily Range 2m 2.56%
Regime Oscillator 79.26
Volatility GJR Garch 1y 29.19%
Price / SMA 50 -1.23%
Price / SMA 200 -0.46%
Current Volume 1960.8k
Average Volume 20d 1686.8k

External Links for INCY Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of INCY stocks?
As of February 22, 2024, the stock is trading at USD 60.33 with a total of 1,960,823 shares traded.
Over the past week, the price has changed by +4.21%, over one month by -1.90%, over three months by +13.34% and over the past year by -23.14%.
Why is INCY stock down?
Check with which Index or Commodity INCY has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return INCY Return S&P 500
1 Month -1.90% 2.85%
3 Months 13.34% 10.14%
12 Months -23.14% 26.48%
What is the forecast for INCY stock price target?
According to ValueRays Forecast Model, INCY Incyte will be worth about 57.2 in February 2025. The stock is currently trading at 60.33. This means that the stock has a potential downside of -5.27%.
Issuer Forecast Upside
Wallstreet Target Price 76.3 26.5%
Analysts Target Price 82.1 36.1%
ValueRay Target Price 57.2 -5.3%